Pentoxifylline XR Shortage: What Providers and Prescribers Need to Know in 2026

Patients prescribed Pentoxifylline XR for intermittent claudication or peripheral artery disease are increasingly reporting difficulty filling their prescriptions at retail pharmacies. While Pentoxifylline XR is not currently on the FDA's official drug shortage list as of 2026, real-world availability challenges persist at the pharmacy level. This briefing summarizes the supply landscape, reviews clinical alternatives, and offers practical strategies for managing affected patients.

Current Availability Status

Pentoxifylline XR (400mg extended-release tablets) is not formally listed on the FDA Drug Shortages Database as of 2026. Multiple generic manufacturers — including Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, Aurobindo Pharma, and Zydus Lifesciences — produce the formulation. Despite this manufacturer diversity, patients frequently report pharmacy-level out-of-stock situations driven by:

Low retail demand leading pharmacies to maintain minimal inventory buffers

Single-source distributor relationships at the individual pharmacy level

Manufacturing complexity of the extended-release polymer matrix formulation

Batch-to-batch variability in smaller production runs for niche generic drugs

Clinical Evidence Review: Positioning Pentoxifylline in PAD Management

It is worth noting that the clinical evidence base for pentoxifylline in intermittent claudication is modest. The AHA/ACC guidelines and the American College of Chest Physicians (ACCP) have both characterized pentoxifylline's effectiveness as marginal or uncertain:

A landmark randomized trial (Dawson et al.) found cilostazol improved maximal walking distance by 54% vs. 30% with pentoxifylline — and pentoxifylline's improvement was statistically indistinguishable from placebo (64m vs. 65m, P=0.82).

The ACCP discourages pentoxifylline for claudication refractory to exercise therapy, citing insufficient evidence.

A 2015 Cochrane systematic review found the quality of included studies generally low with large variability, leaving the drug's role in intermittent claudication uncertain.

Despite these limitations, pentoxifylline retains FDA approval and continues to be prescribed for patients who cannot tolerate cilostazol (primarily those with heart failure) or who require a lower-cost option. For off-label indications including Peyronie's disease, osteoradionecrosis, and certain forms of hepatitis, pentoxifylline may have a more specific role.

Evidence-Based Alternatives for Intermittent Claudication

When prescribing alternatives for patients on Pentoxifylline XR for intermittent claudication, the following considerations apply:

Cilostazol (Pletal): 100mg BID, contraindicated in heart failure (black-box warning). Preferred pharmacological agent per AHA/ACC. FDA-approved for intermittent claudication. Allow 8–12 weeks for assessment of efficacy. Inhibits PDE3; also has antiplatelet and vasodilatory effects.

Supervised Exercise Therapy: Considered the most effective intervention for claudication in multiple meta-analyses and guidelines. Improves walking distance, quality of life, and cardiovascular outcomes. Requires referral to a structured program.

Antiplatelet therapy (clopidogrel, aspirin): Recommended for cardiovascular risk reduction in all PAD patients regardless of symptom management approach. Clopidogrel 75mg QD may be preferred over aspirin for symptomatic PAD based on the CAPRIE trial.

Statin therapy: All PAD patients should be on high-intensity statins for ASCVD risk reduction regardless of LDL levels — this is standard of care and should not be deprioritized during any medication supply gap.

Off-Label Use Scenarios: What to Do During a Gap

For patients receiving pentoxifylline for off-label indications, the alternative pathway will be indication-specific:

Peyronie's disease: Pentoxifylline's antifibrotic mechanism is distinct from other treatments. Consult a urologist for alternative management options.

Osteoradionecrosis / medication-related osteonecrosis: Pentoxifylline is typically used in combination with tocopherol (vitamin E) and sometimes clodronate. A brief gap may be managed with the tocopherol component alone; consult oral and maxillofacial surgery.

Alcoholic hepatitis: The evidence base here has shifted significantly. Corticosteroids remain the primary pharmacological intervention; consult hepatology for current guidance.

Patient Communication Strategies

When patients call your office about unavailability, a clear script helps:

Confirm it's not a formal FDA shortage — direct patients to check multiple pharmacies or use medfinder before assuming it's unavailable everywhere.

For claudication: ask whether a switch to cilostazol is appropriate given their cardiac history.

For patients with heart failure: reinforce supervised exercise therapy and ensure antiplatelet and statin therapy are optimized.

For mail-order: consider writing a 90-day supply prescription to avoid recurring monthly shortfalls.

Tools to Help Your Patients

Consider directing patients to medfinder for providers, a service that calls local pharmacies on behalf of patients to find which ones have Pentoxifylline XR in stock. This reduces patient burden and office call volume when supply issues arise.